Pretreatment PSMA PET enabled a better personalized treatment because pretreatment PSMA PET for patients with HRPC showed that a third of the patients initially had metastatic PCa, whereas conventional imaging only found localized cancer [10]. The gene discussed is FOLH1; the disease is cancer.